Friday, July 10, 2026

Drug profile · INN

calcifediol

calcifediol (RAYALDEE) is a vitamin d receptor agonist. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — calcifediol
US status
approved
Class
Route
ORAL
Patents
0
Programs
3
Data quality
0.84

Quick answer

calcifediol (RAYALDEE) is a vitamin d receptor agonist. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN calcifediol
Brand RAYALDEE
Mechanism Vitamin D receptor agonist
Target Vitamin D3 receptor
Route ORAL
Formulation CAPSULE

Mechanism of action

Vitamin D receptor agonist

Primary target: Vitamin D3 receptor

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. MT-2-02 Phase 2 · Minoryx Therapeutics · CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD)
  2. CFA-1037-1-24 Phase 1 · Tillomed Laboratories · No medical condition.
  3. RES-6128-C1 Approved · Anaxis Pharma · Severe vitamin D deficiency

Related & competitor drugs

  1. calcitriol Vitamin D receptor agonist
  2. doxercalciferol Vitamin D receptor agonist
  3. paricalcitol Vitamin D receptor agonist
  4. calcipotriene Vitamin D receptor agonist
  5. ergocalciferol Vitamin D receptor agonist
  6. calcipotriol + betamethasone dipropionate Vitamin D receptor agonist

Frequently asked questions

What is calcifediol?

calcifediol (RAYALDEE) is a vitamin d receptor agonist. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for calcifediol?

RAYALDEE is a marketed brand name for calcifediol. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of calcifediol?

calcifediol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.